Loading...

APC anti-mouse CD62L Antibody

Pricing & Availability
Clone
MEL-14 (See other available formats)
Regulatory Status
RUO
Other Names
L-selectin, LECAM-1, Ly-22, LAM-1, MEL-14
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
MEL-14_APC_090707
C57BL/6 mouse splenocytes were stained with CD62L (clone MEL-14) APC (filled histogram) or rat IgG2a, κ APC isotype control (open histogram).
  • MEL-14_APC_090707
    C57BL/6 mouse splenocytes were stained with CD62L (clone MEL-14) APC (filled histogram) or rat IgG2a, κ APC isotype control (open histogram).
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
104411 25 µg 66 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
104412 100 µg 193 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD62L is a 74-95 kD glycoprotein also known as L-selectin, LECAM-1, Ly-22, LAM-1, and MEL-14. It is a member of the selectin family and is expressed on the majority of B and naïve T cells, a subset of memory T cells, monocytes, granulocytes, most thymocytes, and a subset of NK cells. CD62L is important in lymphocyte homing to high endothelial venules (HEV) in peripheral lymph nodes and leukocyte "rolling" on activated endothelium. CD62L also contributes to neutrophil emigration at inflammatory sites. CD62L is rapidly shed from lymphocytes and neutrophils upon cellular activation and the expression levels of CD62L (in conjunction with other markers) have been used to distinguish naïve, effector, and memory T cells. CD62L has been reported to interact with CD34, GlyCAM-1, and MAdCAM-1.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
C3H/eb mouse B lymphoma 38C-13
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1-3, complement-dependent cytotoxicity4, in vivo and in vitro blocking of adhesion1-3,5, and immunohistochemical staining of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections6. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 104457-104462).

Application References

(PubMed link indicates BioLegend citation)
  1. Gallatin WM, et al. 1983. Nature 304:30. (IP, Block)
  2. Siegelman MH, et al. 1990. Cell 61:611. (IP, Block)
  3. Lewinsohn DM, et al. 1987. J. Immunol. 138:4313. (IP, Block)
  4. Iwabuchi K, et al. 1991. Immunobiology 182:161. (CMCD)
  5. Pizcueta P, et al. 1994. Am. J. Pathol. 145:461.
  6. Reichert RA, et al. 1986. J. Immunol. 136:3535. (IHC, FC)
  7. Olver S, et al. 2006. Cancer Res. 66:571.
  8. Fukushima A, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:657. PubMed
  9. Benson MJ, et al. 2007. J. Exp. Med. doi:10.1084/jem.20070719. (FC) PubMed
  10. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed
  11. Lee JW, et al. 2006. Nature Immunol. 8:181.
  12. Shigeta A, et al. 2008. Blood 112:4915 (FC) PubMed
  13. de Vries VC, et al. 2009. Am. J. Transplant. 9:2270 PubMed
Product Citations
  1. Jayachandran R, et al. 2019. Immunity. 50:152. PubMed
  2. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  3. Cowan J, et al. 2013. J Exp Med. 210:675. PubMed
  4. Ender F, et al. 2017. PLoS One. 12(2):e0172446. PubMed
  5. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  6. Martens R, et al. 2020. Nat Commun. 11:1114. PubMed
  7. Thi VAD, et al. 2019. Mol Cells. 42:869. PubMed
  8. Hirata Y et al. 2018. Cell stem cell. 22(3):445-453 . PubMed
  9. Shibata K, et al. 2022. Nat Commun. 13:6948. PubMed
  10. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  11. Gabriely G, et al. 2021. iScience. 24:103347. PubMed
  12. Di Martile M, et al. 2020. J Immunother Cancer. 8:. PubMed
  13. Qian Y, et al. 2021. Cell Reports. 36(8):109602. PubMed
  14. Chappaz S, et al. 2021. Cell Reports. 36(3):109430. PubMed
  15. Rezende R, et al. 2015. Nat Commun. 6: 8726. PubMed
  16. Wang J, et al. 2012. Blood. 120:1489. PubMed
  17. Ren S, et al. 2019. Oncol Rep. 41:1509. PubMed
  18. Baptista AP et al. 2019. Immunity. 50(5):1188-1201 . PubMed
  19. Kim CJ, et al. 2018. Immunity. 49:1034. PubMed
  20. Gilleron J et al. 2018. Cell reports. 25(12):3329-3341 . PubMed
  21. Wei H, et al. 2021. Malar J. 20:89. PubMed
  22. Duan Q, et al. 2021. Front Cell Dev Biol. 9:761193. PubMed
  23. Jiang W, et al. 2022. Front Immunol. 13:878832. PubMed
  24. Shapiro MR, et al. 2020. Front Immunol. 1.972222222. PubMed
  25. Mirshahi F, et al. 2022. Cell Rep. 38:110454. PubMed
  26. Zhao Y, et al. 2021. J Biol Chem. 297:101166. PubMed
  27. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  28. Wiese A, et al. 2017. PLoS One. 10.1371/journal.pone.0184956. PubMed
  29. Roy S, et al. 2020. Sci Rep. 10:10992. PubMed
  30. Yoon Y, et al. 2021. Cancers (Basel). 13: . PubMed
  31. Zhou HF, et al. 2022. Front Pharmacol. 13:778755. PubMed
  32. Nagaoka M, et al. 2014. J Immunol. 193:2812. PubMed
  33. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  34. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  35. Sasaki K, et al. 2019. Nat Commun. 10:3878. PubMed
  36. Li Y, et al. 2020. Nat Commun. 11:2781. PubMed
  37. Parriott G, et al. 2020. Immunology. 160:280. PubMed
  38. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  39. Guo Z, et al. 2016. Nat Commun. 7:10307. PubMed
  40. Ma X et al. 2019. Cell Metab. 30(1):143-156 . PubMed
  41. Yu Y, et al. 2022. Nat Commun. 13:6357. PubMed
  42. Phiwpan K, et al. 2015. PLoS One. 10:128198. PubMed
  43. Luo Y et al. 2019. Cell reports. 26(7):1869-1879 . PubMed
  44. Deng B, et al. 2022. J Immunother Cancer. 10:. PubMed
  45. Chen L, et al. 2021. Cell Death Differ. 28:1880. PubMed
  46. Sinclair LV et al. 2019. Elife. 8 pii: e44210. PubMed
  47. Yue X, et al. 2019. Nat Commun. 10:2011. PubMed
  48. Lu Y, et al. 2021. Gastroenterology. 161:575. PubMed
  49. Kondratieva T, et al. 2020. PLoS One. 15:e0239668. PubMed
  50. Chin AL, et al. 2021. Nat Commun. 12:5138. PubMed
  51. Darragh LB, et al. 2022. Nat Commun. 13:7015. PubMed
  52. Qi T, et al. 2020. Cell Rep. 33:108452. PubMed
  53. Ruer-Laventie J, et al. 2020. Bio Protoc. e3531:10. PubMed
  54. Yang W, et al. 2020. Methods Mol Biol. 2111:91. PubMed
  55. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  56. Kulkarni R, et al. 2021. PLoS One. 16:e0257191. PubMed
  57. Glassman CR, et al. 2021. eLife. 10:00. PubMed
  58. Fu X, et al. 2020. Aging (Albany NY). 12:15656. PubMed
  59. Su X, et al. 2022. J Transl Med. 20:378. PubMed
  60. Coquery C, et al. 2014. PLoS One. 9:102284. PubMed
  61. Cowan J, et al. 2014. J Immunol. 193:1204. PubMed
  62. White C, et al. 2015. J Immunol. 194:697. PubMed
  63. Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
  64. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  65. Morimoto Y, et al. 2018. Immunity. 49:134. PubMed
  66. Biton M et al. 2018. Cell. 175(5):1307-1320 . PubMed
  67. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  68. Covarrubias AJ, et al. 2020. Nat Metab. 1265:2. PubMed
  69. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  70. Kretschmer L, et al. 2020. Nat Commun. 0.536805556. PubMed
  71. Ma K, et al. 2022. iScience. 25:104347. PubMed
  72. Borges da Silva H, et al. 2020. Immunity. 53(1):158-171.e6. PubMed
  73. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  74. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  75. Liu YG, et al. 2019. FASEB J. 33:5018. PubMed
  76. Resch TK, et al. 2018. Sci Rep. 0.722916667. PubMed
  77. Roy S, et al. 2021. Nat Commun. 12:3182. PubMed
  78. Do-Thi VA, et al. 2021. Cancers (Basel). 13:. PubMed
  79. Jenkinson W, et al. 2012. PLoS One. 7:e53416. PubMed
  80. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  81. Amezcua Vesely MC, et al. 2020. Cell. 178(5):1176-1188.e15.. PubMed
  82. Fan MY et al. 2018. Cell reports. 25(5):1204-1213 . PubMed
  83. Asadi Shahmirzadi A, et al. 2020. Cell Metabolism. 32(3):447-456.e6. PubMed
  84. Shimba A et al. 2018. Immunity. 48(2):286-298 . PubMed
  85. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  86. Kim S, et al. 2022. Cancers (Basel). 14:. PubMed
  87. Wagner AK, et al. 2022. iScience. 25:105137. PubMed
  88. Fedele C, et al. 2021. J Exp Med. 218: . PubMed
  89. Schaffert S, et al. 2015. J Immunol. 195: 1470-1479. PubMed
  90. Hoechst B, et al. 2016. J Immunol. 195:1517-1523. PubMed
  91. Xu Y, et al. 2016. Nat Commun. 7:12073. PubMed
  92. Webb LM, et al. 2020. J Clin Invest. 130:1683. PubMed
  93. Lin JD, et al. 2020. Cell Host & Microbe. 27(5):830-840. PubMed
  94. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  95. Parks CA, et al. 2019. Proc Natl Acad Sci U S A. 116:3136. PubMed
  96. Yue T, et al. 2022. Cell Death Differ. 29:218. PubMed
  97. Rochford I, et al. 2021. Am J Physiol Lung Cell Mol Physiol. 321:L686. PubMed
  98. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  99. Kooijman S, et al. 2015. Am J Physiol Heart Circ Physiol. 309: H646-H654. PubMed
  100. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  101. Angela M, et al. 2016. Nat Commun. 7:13683. PubMed
  102. Katsuyama T, et al. 2021. Cell Reports. 36(1):109339. PubMed
  103. Louise V Webb et al. 2019. Immunity. 50(2):348-361 . PubMed
  104. Chen S, et al. 2018. Nat Commun. 9:5298. PubMed
  105. Hodgson R, et al. 2022. Commun Biol. 5:1216. PubMed
  106. Jiang W, et al. 2021. Cell Rep. 37:110112. PubMed
  107. Chang MH, et al. 2021. Cell Rep. 37:109902. PubMed
  108. Yu Z, et al. 2021. Biomed Res Int. 2021:9958745. PubMed
  109. Bae S, et al. 2021. Cell Reports. 35(11):109264. PubMed
RRID
AB_313098 (BioLegend Cat. No. 104411)
AB_313099 (BioLegend Cat. No. 104412)

Antigen Details

Structure
Selectin, 95 kD (neutrophils) or 74 kD (lymphocytes)
Distribution

Subsets of B and T cells, monocytes, granulocytes, subset of NK cells

Function
Lymphocyte homing to HEV, rolling on activated endothelium
Ligand/Receptor
CD34, GlyCAM-1, MAdCAM-1
Cell Type
B cells, Granulocytes, Monocytes, Neutrophils, NK cells, T cells, Tregs
Biology Area
Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Kishimoto TK, et al. 1990. P. Natl. Acad. Sci. USA 87:2244.
3. Tedder TF, et al. 1995. J. Exp. Med. 181:2259.

Gene ID
20343 View all products for this Gene ID
UniProt
View information about CD62L on UniProt.org
Go To Top Version: 1    Revision Date: 11.30.2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account